DR. MINAL ATUL BARVE M.D. NPI 1245277698

NPI Details

DR. Minal Atul Barve, M.D. is a medical oncology internal medicine in Dallas, TX with 33 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Minal Atul Barve, M.D. NPI is 1245277698. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

8220 WALNUT HILL LN
SUITE 700
DALLAS, TX
ZIP 75231-427
Phone: (214) 739-4175
Fax: (214) 987-4161

The NPI 1245277698 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Magnesium level (HCPCS:83735)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Uric acid level, blood (HCPCS:84550)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Unclassified drugs (HCPCS:J3490)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection of drug or substance into vein (HCPCS:96374)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)

The enumeration date for this NPI number is 6/1/2006 and was last updated on 8/14/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.